A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, 2-treatment, 2-period, 2-sequence, crossover study, The study will
consist of a screening visit, study center admission (preceding Treatment Periods 1 and 2), 2
treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1 and 2),
and exit procedures.